Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
They also had a higher prevalence of obesity, hypertension and diabetes, exhibited higher eGFR and hs-CRP levels, and had lower vitamin D levels compared with the included participants.
Source: Selection of participants. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Finally, 4047 participants were included in this study (Fig.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Exploring the relationship between serum magnesium levels, genetic variants and chronic kidney disease: a prospective study
Study design awaiting verification · Clinical Kidney Journal · 2025
Original publication title
Exploring the relationship between serum magnesium levels, genetic variants and chronic kidney disease: a prospective study
© The Author(s) 2025. Published by Oxford University Press on behalf of the ERA.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Recent evidence suggests that magnesium deficiency may play a role in the development and progression of chronic kidney disease (CKD). We assessed the association between genetic variations, serum magnesium levels and CKD risk in the general population.
Source: BackgroundAbstract: What methods does the paper describe?
In this population-based prospective study (n = 4047; mean age 53 years; 54% female; mean follow-up 12.5 years), Cox regression models evaluated the effects of hypomagnesemia on CKD risk. Genetic risk scores and mediation analyses were used to assess the direct and indirect effects of single-nucleotide polymorphisms (SNPs) on CKD development through magnesium levels. One-sample and two-sample Mendelian randomization (MR) analyses were conducted to examine the causal relationship between genetically predicted serum magnesium levels and CKD risk.
Source: MethodsAbstract: Results
Multivariable Cox regression analyses identified that hypomagnesemia was significantly associated with an increased risk of CKD, with a hazard ratio of 1.73 (95% confidence interval 1.14 to 2.61, P = .010). Analyses based on single SNPs and SNP scores did not reveal direct effects on CKD risk. Mediation analyses demonstrated that four SNPs exerted significant indirect effects on CKD risk through serum magnesium levels. However, the proportion of the total effect mediated by magnesium was low and not statistically significant. MR analyses did not provide strong evidence for a significant causal relationship between genetically predicted magnesium levels and CKD risk.
Source: ResultsAbstract: Conclusions
Hypomagnesemia was significantly associated with an increased risk of long-term CKD. Genetic analysis suggests that serum magnesium levels may play an indirect role in CKD risk, but no clear causal relationship was found.
Source: ConclusionsAuthors’ abstract
ABSTRACT
Background
Recent evidence suggests that magnesium deficiency may play a role in the development and progression of chronic kidney disease (CKD). We assessed the association between genetic variations, serum magnesium levels and CKD risk in the general population.
Methods
In this population-based prospective study (n = 4047; mean age 53 years; 54% female; mean follow-up 12.5 years), Cox regression models evaluated the effects of hypomagnesemia on CKD risk. Genetic risk scores and mediation analyses were used to assess the direct and indirect effects of single-nucleotide polymorphisms (SNPs) on CKD development through magnesium levels. One-sample and two-sample Mendelian randomization (MR) analyses were conducted to examine the causal relationship between genetically predicted serum magnesium levels and CKD risk.
Results
Multivariable Cox regression analyses identified that hypomagnesemia was significantly associated with an increased risk of CKD, with a hazard ratio of 1.73 (95% confidence interval 1.14 to 2.61, P = .010). Analyses based on single SNPs and SNP scores did not reveal direct effects on CKD risk. Mediation analyses demonstrated that four SNPs exerted significant indirect effects on CKD risk through serum magnesium levels. However, the proportion of the total effect mediated by magnesium was low and not statistically significant. MR analyses did not provide strong evidence for a significant causal relationship between genetically predicted magnesium levels and CKD risk.
Conclusions
Hypomagnesemia was significantly associated with an increased risk of long-term CKD. Genetic analysis suggests that serum magnesium levels may play an indirect role in CKD risk, but no clear causal relationship was found.
Publication and source details
Original title: Exploring the relationship between serum magnesium levels, genetic variants and chronic kidney disease: a prospective study
Sisi Xie; Idris Guessous; Dela Golshayan; Aurélien Thomas; Julien Vaucher; Pedro Marques-Vidal
Clinical Kidney Journal · 2025
Correspondence to: Pedro Marques-Vidal; E-mail: Pedro-Manuel.Marques-Vidal@chuv.ch© The Author(s) 2025. Published by Oxford University Press on behalf of the ERA.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. GlaxoSmithKline10.13039/100004330 Swiss National Science Foundation10.13039/501100001711 33CSCO-12266133CS30-13946833CS30-14840133CS30_17753531003A-1824203247730_204523 Swiss Personalized Health Network 2018DRI01 Fondation pour la recherche sur le diabèteRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:29:54.005416+00:00
DOI: 10.1093/ckj/sfaf254 · PMC13014121